GSK's $3B Takeover Of Human Genome Survives 2 Challenges

Human Genome Sciences Inc. on Thursday beat back two shareholder challenges to its $3 billion takeover by GlaxoSmithKline PLC, securing rejections of motions seeking to delay the close of the tender...

Already a subscriber? Click here to view full article